Mangoceuticals, Inc. (NASDAQ:MGRX) Financings
Financings
| Raise | Date |
|---|---|
| Series D Cumulative Convertible Preferred Stock (tokenized) Announced: up to US$10M · US$10 a share Use of proceeds: General corporate purposes and working capital | Nov 12, 2026 |
| Registered direct offering of units of one share of common stock and one warrant Closed: US$500,000 raised · US$0.75 a unit · one warrant Use of proceeds: Additional working capital | Oct 9, 2026 |
| Strategic investment of membership interests in MangoRx IP Holdings, LLC Tranche closed: US$1.75M raised Use of proceeds: To advance commercialization of the antiviral intellectual property portfolio held by MangoRx IP | Oct 1, 2026 |
| Registered direct offering of common Units (or Pre-Funded Units) of common stock and PIPE common warrants Closed: US$2.5M raised · US$1.295 a unit · Warrants at US$1.4245 · Aegis Capital Corp. Dealers: Aegis Capital Corp. (lead) Use of proceeds: General corporate purposes and working capital | Dec 19, 2025 |